Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.91
+0.52003.17%
Post-market: 16.910.0024+0.01%18:34 EDT
Volume:13.05M
Turnover:224.03M
Market Cap:13.49B
PE:-15.13
High:17.72
Open:16.59
Low:16.17
Close:16.39
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.41
T/O Rate:8.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.41
PE(LYR):-11.71

Loading ...

AstraZeneca: Each Co Will Retain Development and Commercial Rights to Their Respective Medicines

THOMSON REUTERS
·
Sep 29

AstraZeneca Broadens Oncology Portfolio Through Summit Deal

Dow Jones
·
Sep 29

Toyota Land Cruiser 2026: Old-school 4×4 ready for anything

cityam
·
Sep 29

UK Stocks-Factors to Watch on September 29

Reuters
·
Sep 29

Summit Therapeutics Inc. : Jefferies Raises Target Price to $30 from $25

THOMSON REUTERS
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

24H | Summit Therapeutics Surges 18%; Navitas Semiconductor Jumps 12%; Fair Isaac Sinks 9%

US Overnight
·
Sep 29

Movement Alert|Summit Therapeutics PLC Overnight Rise 17.96%, AstraZeneca Invests $2 Billion in Convertible Preferred Shares and Clinical Collaboration

Market Focus
·
Sep 29

AstraZeneca to Invest $2 Billion in Summit Therapeutics for Cancer Drug Tie-up

Reuters
·
Sep 29

Stocks to Watch: Summit Therapeutics, Sangoma, Navitas

Dow Jones
·
Sep 29

Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment

TIPRANKS
·
Sep 29

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

TIPRANKS
·
Sep 29

AstraZeneca makes $2B equity investment in Summit Therapeutics

TIPRANKS
·
Sep 29

Movement Alert|Summit Therapeutics PLC Rises 17.39% in After-Hours Trading, Multiple Late-Stage Clinical Catalysts Drive Momentum

Market Focus
·
Sep 29

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

THOMSON REUTERS
·
Sep 29

Summit Therapeutics - Co and AstraZeneca Plan Clinical Trial Collaboration for Ivonescimab with Multiple AstraZeneca Adcs

THOMSON REUTERS
·
Sep 29

Summit Therapeutics - Investment in Convertible Preferred Shares at $18.36 Per Share, Premium to Closing Price

THOMSON REUTERS
·
Sep 29

AstraZeneca Makes $2 Billion Equity Investment in Summit Therapeutics Via Convertible Preferred Shares

Reuters
·
Sep 29

Bernstein Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 26

Piper Sandler Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 25